
Claims

1. A compound of formula (I)



(I)

or a stereoisomeric form thereof, wherein

R^1 is chloro, trifluoromethyl or cyano;

R^2 is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylsulfonyl, perfluoroC_{1-4}alkyl, perfluoroC_{1-4}alkyloxy, diC_{1-4}alkylamino, hydroxyl, and phenyl optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C_{1-4}alkyl and perfluoroC_{1-4}alkyl; thienyl; thienyl substituted with 1 or 2 substituents each independently selected from the group consisting of halo and C_{1-4}alkyl; naphthyl; pyridinyl; pyrrolyl; benzothiazolyl; indolyl; quinolinyl; C_{3-8}cycloalkyl; or C_{5-7}cycloalkenyl;

R^3 is hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxy or halo;

R^4 and R^5 are each independently hydrogen or C_{1-4}alkyl, or R^4 and R^5 together form C_{1-4}alkanediyl;

n is 1 or 2; and

R^6 is hydrogen, C_{1-4}alkyl, hydroxyC_{2-4}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, pyridinylmethyl, or phenylmethyl optionally substituted on the phenyl with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylsulfonyl, perfluoroC_{1-4}alkyl, perfluoroC_{1-4}alkyloxy and diC_{1-4}alkylamino ; or R^5 and R^6 together form C_{2-5}alkanediyl;

or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1 wherein

R^1 is chloro, trifluoromethyl or cyano;

R^2 is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylsulfonyl, perfluoroC_{1-4}alkyl, perfluoroC_{1-4}alkyloxy, diC_{1-4}alkylamino,

hydroxyl, and phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C_{1-4}alkyl and perfluoroC_{1-4}alkyl; thienyl; thienyl substituted with 1 or 2 substituents each independently selected from the group consisting of halo and C_{1-4}alkyl; naphthyl; pyridinyl; pyrrolyl; benzothiazolyl; indolyl; quinolinyl; C_{3-8}cycloalkyl; or C_{5-7}cycloalkenyl;
R^3 is hydrogen, C_{1-4}alkyl or halo;
R^4 and R^5 are each independently hydrogen or C_{1-4}alkyl, or R^4 and R^5 together form C_{1-4}alkanediyl;
n is 1 or 2; and
R^6 is hydrogen, C_{1-4}alkyl, hydroxyC_{2-4}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-4}alkyl, or phenylmethyl substituted on the phenyl with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylsulfonyl, perfluoroC_{1-4}alkyl, perfluoroC_{1-4}alkyloxy and diC_{1-4}alkylamino ; or R^5 and R^6 together form C_{2-5}alkanediyl;
or a pharmaceutically acceptable salt or solvate thereof.

3. A compound according to claim 1 wherein
R^1 is trifluoromethyl or cyano;
R^2 is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylsulfonyl, perfluoroC_{1-4}alkyl, diC_{1-4}alkylamino, hydroxyl, and phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C_{1-4}alkyl and perfluoroC_{1-4}alkyl; thienyl; thienyl substituted with 1 or 2 substituents each independently selected from the group consisting of halo and C_{1-4}alkyl; naphthyl; pyridinyl; pyrrolyl; benzothiazolyl; indolyl; quinolinyl; C_{3-8}cycloalkyl; or C_{5-7}cycloalkenyl;
R^3 is hydrogen;
R^4 and R^5 are each independently hydrogen or C_{1-4}alkyl;
n is 1;
R^6 is hydrogen, methyl, ethyl, cyclopropyl, or phenylmethyl substituted on the phenyl with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylsulfonyl, perfluoroC_{1-4}alkyl and diC_{1-4}alkylamino ; or R^5 and R^6 together form C_{2-5}alkanediyl;
or a pharmaceutically acceptable salt or solvate thereof.

4. A compound according to claim 1 wherein
R^1 is trifluoromethyl;
R^2 is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylsulfonyl, perfluoroC_{1-4}alkyl, diC_{1-4}alkylamino, hydroxyl, and phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C_{1-4}alkyl and perfluoroC_{1-4}alkyl; thienyl; thienyl substituted with 1 or 2 substituents each independently selected from the group consisting of halo and C_{1-4}alkyl; naphthyl; pyridinyl; pyrrolyl; benzothiazolyl; indolyl; quinolinyl; C_{3-8}cycloalkyl; or C_{5-7}cycloalkenyl;
R^3 is hydrogen;
R^4 and R^5 are each independently hydrogen or methyl;
n is 1;
R^6 is hydrogen, ethyl or (3,5-difluorophenyl)methyl; or
R^5 and R^6 together form 1,3-propanediyl;
or a pharmaceutically acceptable salt or solvate thereof.

5. A compound according to claim 1 wherein the compound is 4-phenyl-6-piperazin-1-yl-3-trifluoromethyl-pyridazine.

6. A compound according to claim 1 wherein the compound is 4-phenyl-6-piperazin-1-yl-3-trifluoromethyl-pyridazine monohydrochloride.


7. A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim 1.

8. A compound as defined in claim 1 for use as a medicine.

9. A compound as defined in claim 8 for use as an antipsychotic.

Claims

1. A compound of formula (I)



(I)

or a stereoisomeric form thereof, wherein
R^1 is chloro, trifluoromethyl or cyano;
R^2 is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylsulfonyl, perfluoroC_{1-4}alkyl, perfluoroC_{1-4}alkyloxy, diC_{1-4}alkylamino, hydroxyl, and phenyl optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C_{1-4}alkyl and perfluoroC_{1-4}alkyl; thienyl; thienyl substituted with 1 or 2 substituents each independently selected from the group consisting of halo and C_{1-4}alkyl; naphthyl; pyridinyl; pyrrolyl; benzothiazolyl; indolyl; quinolinyl; C_{3-8}cycloalkyl; or C_{5-7}cycloalkenyl;
R^3 is hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxy or halo;
R^4 and R^5 are each independently hydrogen or C_{1-4}alkyl, or R^4 and R^5 together form C_{1-4}alkanediyl;
n is 1 or 2; and
R^6 is hydrogen, C_{1-4}alkyl, hydroxyC_{2-4}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, pyridinylmethyl, or phenylmethyl optionally substituted on the phenyl with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylsulfonyl, perfluoroC_{1-4}alkyl, perfluoroC_{1-4}alkyloxy and diC_{1-4}alkylamino ; or R^5 and R^6 together form C_{2-5}alkanediyl;
or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1 wherein
R^1 is chloro, trifluoromethyl or cyano;
R^2 is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylsulfonyl, perfluoroC_{1-4}alkyl, perfluoroC_{1-4}alkyloxy, diC_{1-4}alkylamino, hydroxyl, and phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C_{1-4}alkyl and perfluoroC_{1-4}alkyl; thienyl; thienyl substituted with 1 or 2 substituents each independently selected from the group consisting of halo and C_{1-4}alkyl; naphthyl; pyridinyl; pyrrolyl; benzothiazolyl; indolyl; quinolinyl; C_{3-8}cycloalkyl; or C_{5-7}cycloalkenyl;
R^3 is hydrogen, C_{1-4}alkyl or halo;
R^4 and R^5 are each independently hydrogen or C_{1-4}alkyl, or R^4 and R^5 together form C_{1-4}alkanediyl;
n is 1 or 2; and
R^6 is hydrogen, C_{1-4}alkyl, hydroxyC_{2-4}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-4}alkyl, or phenylmethyl substituted on the phenyl with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylsulfonyl, perfluoroC_{1-4}alkyl, perfluoroC_{1-4}alkyloxy and diC_{1-4}alkylamino ; or R^5 and R^6 together form C_{2-5}alkanediyl;
or a pharmaceutically acceptable salt or solvate thereof.

3. A compound according to claim 1 wherein
R^1 is trifluoromethyl or cyano;
R^2 is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylsulfonyl, perfluoroC_{1-4}alkyl, diC_{1-4}alkylamino, hydroxyl, and phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C_{1-4}alkyl and perfluoroC_{1-4}alkyl; thienyl; thienyl substituted with 1 or 2 substituents each independently selected from the group consisting of halo and C_{1-4}alkyl; naphthyl; pyridinyl; pyrrolyl; benzothiazolyl; indolyl; quinolinyl; C_{3-8}cycloalkyl; or C_{5-7}cycloalkenyl;
R^3 is hydrogen;
R^4 and R^5 are each independently hydrogen or C_{1-4}alkyl;
n is 1;
R^6 is hydrogen, methyl, ethyl, cyclopropyl, or phenylmethyl substituted on the phenyl with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylsulfonyl, perfluoroC_{1-4}alkyl and diC_{1-4}alkylamino ; or R^5 and R^6 together form C_{2-5}alkanediyl;

or a pharmaceutically acceptable salt or solvate thereof.

4. A compound according to claim 1 wherein
R^1 is trifluoromethyl;
R^2 is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylsulfonyl, perfluoroC_{1-4}alkyl, diC_{1-4}alkylamino, hydroxyl, and phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C_{1-4}alkyl and perfluoroC_{1-4}alkyl; thienyl; thienyl substituted with 1 or 2 substituents each independently selected from the group consisting of halo and C_{1-4}alkyl; naphthyl; pyridinyl; pyrrolyl; benzothiazolyl; indolyl; quinolinyl; C_{3-8}cycloalkyl; or C_{5-7}cycloalkenyl;
R^3 is hydrogen;
R^4 and R^5 are each independently hydrogen or methyl;
n is 1;
R^6 is hydrogen, ethyl or (3,5-difluorophenyl)methyl; or
R^5 and R^6 together form 1,3-propanediyl;
or a pharmaceutically acceptable salt or solvate thereof.

5. A compound according to claim 1 wherein the compound is 4-phenyl-6-piperazin-1-yl-3-trifluoromethyl-pyridazine.

6. A compound according to claim 1 wherein the compound is 4-phenyl-6-piperazin-1-yl-3-trifluoromethyl-pyridazine monohydrochloride.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim 1.

8. A compound as defined in claim 1 for use as a medicine.

9. A compound as defined in claim 8 for use as an antipsychotic.

10. A compound as defined in claim 8 for use as a medicine in the treatment or prevention of schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, psychotic disorder not otherwise specified; psychosis associated with dementia; major depressive disorder, dysthymic disorder, premenstrual dysphoric disorder, depressive disorder not otherwise specified, Bipolar I disorder, bipolar II disorder, cyclothymic disorder, bipolar disorder not otherwise specified, mood disorder due to a general medical condition, substance-induced mood disorder, mood disorder not otherwise specified; generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, acute stress disorder, post-traumatic stress disorder; mental retardation; pervasive developmental disorders; attention deficit disorders, attention-deficit/hyperactivity disorder, disruptive behaviour disorders; personality disorder of the paranoid type, personality disorder of the schizoid type, personality disorder of the schizotypical type; tic disorders, Tourette's syndrome; substance dependence; substance abuse; substance withdrawal; trichotillomania; and conditions wherein cognition is impaired; Alzheimer's disease, Parkinson's disease, Huntingdon's disease, Lewy Body Dementia, dementia due to HIV disease, dementia due to Creutzfeldt-Jakob disease; amnestic disorders; mild cognitive impairment; and age-related cognitive decline; and feeding disorders such as anorexia and bulimia; and obesity.